Assess whether to resubmit, meet, or pause the program (488e40)

SITUATION Labeling negotiator owns this FDA Response and Labeling review in a biologics company planning a biosimilar pathway. An FAERS cluster in a demographic the trials under-enrolled is the triggering event; 505(b)(2) literature-to-product bridge table is the evidence for whether to resubmit, meet, or pause the program.

DECISION Labeling negotiator in a biologics company planning a biosimilar pathway must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Labeling negotiator can defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. Labeling negotiator cannot defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table; Pause the program is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to resubmit, meet, or. 4. Two facts in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled conflict for labeling negotiator; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled). The follow-on FDA Response and Labeling action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for labeling negotiator - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - What changes to resubmit, meet, or if an FAERS cluster in a demographic the trials under-enrolled is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others